Todd Herron, Director of our hiPSC BioBank at Greenstone Biosciences, will be a co-chair for the session “From Bench to Benefit-Cardiac NAMs for Predictive Safety and Efficacy Assessment” on September...

BioPharma

Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical tri...

Cardiac disease remains the leading cause of mortality in Duchenne muscular dystrophy, yet therapeutic options remain limited. Greenstone Biosciences has been awarded a Catalyze R61 grant from the Nat...

Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.

PTEN Hamartoma Tumor Syndrome is a rare inherited condition caused by changes in the PTEN gene. People living with PHTS can experience a wide range of health challenges, including developmental differ...

The FDA’s push to reduce reliance on animal testing is a call to action for platforms built to replace it. Greenstone Biosciences’ iPSC biobank includes more than 2,500 patient-derived lines spanning...

On June 22, HHS unveiled Operation TrialBlazer, a coordinated initiative to accelerate clinical research across the full development pipeline, from IND submission through late-stage pivotal trials, in...

First Microphysiological Systems World Summit. Explore the details on presenters, registration and in person or on-line participation.

First Microphysiological Systems World Summit. Explore the details on presenters, registration and in person or on-line participation.

BackgroundSudden cardiac death is a common but poorly understood cause of mortality in Fabry disease (FD). We investigated the arrhythmogenic mechanisms usin...

YouTube video by Greenstone Biosciences

This article explores innovations helping organoids reach their enormous potential. From vascularized tissues to fused assembloids and embedded bioelectronics, these miniature cell models are evolving...

YouTube video by Greenstone Biosciences

We are thrilled to see our Co-Founder Joseph C. Wu featured in a news article in Nature Magazine exploring the future of biomedical research and the global shift away from animal testing. As governme...

Greenstone Biosciences is offering specialized patient-derived induced pluripotent stem cell (iPSC)-derived lines carrying Emery-Dreifuss muscular dystrophy (EDMD)–associated mutations to help researc...

Dr. Joseph Wu is a Professor of Medicine and Radiology and the Director of the Stanford Cardiovascular Institute. He talks about the importance of pharmacology knowledge in drug discovery. He also dis...

Greenstone Biosciences is offering specialized patient-derived induced pluripotent stem cell (iPSC)-derived lines carrying Facioscapulohumeral muscular dystrophy (FSHD)–associated mutations to help re...

YouTube video by Greenstone Biosciences

Earlier this week, the U.S. Senate unanimously passed the FDA Modernization Act 3.0. This bill will require the FDA to update its regulations to replace references to “animal” testing with “nonclinica...

Recently, the FDA unveiled a major regulatory innovation: the Plausible Mechanism Pathway, a new approval route that allows certain therapies—especially those targeting rare genetic diseases—to obtain...

Our latest post in Greenstone Biosciences’ gut organoid series highlights how we support researchers in evaluating gastrointestinal (GI) toxicity using human-relevant in-vitro systems. We use a range...

This week, the UK government announced an ambitious plan backed by £75 million to accelerate the transition toward human-relevant alternative methods, including organ-on-chip systems, advanced AI mode...